Certolizumab pegol in the treatment of axial spondyloarthritis

Axial spondyloarthritis is a chronic, immune-mediated systemic inflammatory disease encompassing ankylosing spondylitis and nonradiographic axial spondyloarthritis. TNF inhibitors are the preferred second line therapy for patients with active axial spondyloarthritis. Certolizumab pegol is a TNF inhi...

Full description

Saved in:
Bibliographic Details
Published inImmunotherapy
Main Authors Anderson, Elizabeth, Beier, Secia, Desmarais, Julianna
Format Journal Article
LanguageEnglish
Published England 27.04.2024
Subjects
certolizumab pegol
nonradiographic axial spondyloarthritis
axial spondyloarthritis
ankylosing spondylitis
Online AccessGet more information

Cover

More Information
Summary:Axial spondyloarthritis is a chronic, immune-mediated systemic inflammatory disease encompassing ankylosing spondylitis and nonradiographic axial spondyloarthritis. TNF inhibitors are the preferred second line therapy for patients with active axial spondyloarthritis. Certolizumab pegol is a TNF inhibitor approved for treatment of both. Three large phase III trials (RAPID-axSpA, C-axSpAnd and C-OPTIMISE) and one large phase IV trial (CIMAX) establish its clinical efficacy in treatment of active disease and maintenance of remission for both diseases. Real world evidence demonstrates clinical efficacy and benefits including reduced bone loss, reduced risk of uveitis, safety in pregnancy and lactation and index drug survival of 10 years. It is generally well tolerated, though can be associated with increased risk of serious infections.
ISSN:1750-7448
DOI:10.2217/imt-2023-0225